The role of HMGB1 in inflammatory response and vulnerable plaque in coronary heart disease

Abstract

Abstract: Objective To study the relationship between the levels of HMGB1, MMP-9, and the stability of coronary artery atheromatous plaque, to further discover the relationship among immune response, inflammatory reaction and coronary heart disease.Method Fifty-eight coronary heart disease patients who were cured between - August 2013 to January 2014 in Guangdong Province Hospital Of Traditional Chinese Medicine were enrolled. Thirty healthy individuals who were cured during the same time in our hospital without structural heart disease (but with normal heart function) were enrolled as control group. ELISA kit was used to detect the HMGB1, MMP-9, concentration of stored examples.Result i) Serum HMGB1 level was gradually increased in the control groups, considering the SA, UA and AMI groups, and it indicated a significant statistic difference(P<0.05); and is higher than the controls. ii) Serum level of MMP-9 was significantly higher in coronary heart disease groups than the control group, and it indicated a significant statistic difference(P<0.05). iii) Serum levels of HMGB1、MMP-9 were also significantly different, HMGB1 and MMP-9 levels correlated positively (r=0.463 P<0.05).Conclusion HMGB1 has certain correlation with clinical routine detection of inflammation, blood lipid and other indicators, it could be inferred that HMGB1 was an independent factor of CHD classification, and could indirectly reflect the degree of active inflammation in plaque. HMGB1 was also positively correlated with MMP-9, suggesting that the detection of HMGB1 could predict plaque stability to a certain extent and provide a reliable basis for the anti-inflammatory treatment of coronary heart disease.

Key words: Coronary heart disease, Inflammatory, High mobility group box protein 1, Matrix metallo proteinase-9

HU Ya-nan, DU Shao-hui, CHEN Si-nuo, HU Tian-xiang. The role of HMGB1 in inflammatory response and vulnerable plaque in coronary heart disease[J]. Electronic Journal of Emerging Infectious Diseases, 2017, 2(3): 179-182.

References

[1] Goodwin G H, Johns E W.Isolation and characterization of two cal-f thymus chro-matinnon-histoneproteins with high ontents of acidic and basic amino acids[J]. Eur JBiochem, 1973, 40(1): 215-219.
[2] Eriksson E E, Xie X, Werr J, et al.Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo[J]. J Exp Med, 2001, 194(2): 205-218.
[3] Stemme S, Faber B, Holm J, et al.T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein[J]. Proc Natl Acad Sci U S A, 1995, 92(9): 3893-3897.
[4] Madhur M S, Funt S A, Li L, et al.Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2011, 31(7): 1565-1572.
[5] Ross R.The pathogenesis of atherosclerosis--an update[J]. N Engl J Med, 1986, 314(8): 488-500.
[6] Peter Libby.Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy .N Engl [J] Med.2013.368; 2004-2013.
[7] Hansson G K, Hellstrand M, Rymo L, et al.Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells[J]. J Exp Med, 1989, 170(5): 1595-1608.
[8] Amento E P, Ehsani N, Palmer H, et al.Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells[J]. Arterioscler Thromb, 1991, 11(5): 1223-1230.
[9] Jin DQ,Wu YB, Zhao L et al. Atorvastatin reduces serum HMGBl levels in patients with hyperlipidemia[J], Exp Ther Med,2012,4(l): 1124-1126.
[10] Kalinina N, Agrotis A, Antropova Y, et al.Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines[J]. Arterioscler Thromb Vasc Biol, 2004, 24(12): 2320-2325.
[11] Porto A, Palumbo R, Pieroni M, et al.Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein[J]. FASEB J, 2006, 20(14): 2565-2566.
[12] de Souza A W, Westra J, Limburg P C, et al. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis[J]. Autoimmun Rev, 2012, 11(12): 909-917.
[13] Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M,et al.HMGBl expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques[J], Cardiovasc Patho 2007;16(2): 136-143.
[14] Monroe V S, Kerensky R A, Rivera E, et al.Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes[J]. J Am Coll Cardiol, 2003, 41(4 Suppl S): 23S-30S.
[15] Dodd T, Jadhav R, Wiggins L, et al.MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK[J]. J Mol Cell Cardiol, 2011, 51(6): 1015-1025.
[16] Brown D L, Hibbs M S, Kearney M, et al.Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina[J]. Circulation, 1995, 91(8): 2125-2131.
[17] 史恒川,刘俊恒,朱建一.老年冠心病患者血清白细胞介素6及高迁移率蛋白B1水平的观察[J].实用老年医学,2011,25(5);412-414.